ORIGINAL RESEARCH article
Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1594682
This article is part of the Research TopicPrognostic Biomarkers and Gene Signatures in Endometrial, Ovarian, and Cervical CancerView all 19 articles
A Lipid Metabolism and Lysosome-based Risk Signature for Prognosis and Immune Response Prediction in Uterine Corpus Endometrial Carcinoma
Provisionally accepted- 1Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- 2Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai Municipality, China
- 3Department of Gynecology & Obstetrics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The dysregulation of genes related to lipid metabolism and lysosomal function has been reported to significantly contribute to tumor progression. In this study, we systematically explored the roles played by lipid metabolism and lysosomes in uterine corpus endometrial carcinoma (UCEC), aiming to identify potential biomarkers for predicting prognosis and immune checkpoint therapy efficacy. Methods: Genes associated with lipid metabolism and lysosomal function were retrieved from the MSigDB and GO databases. Transcriptomic data and clinical information of patients were acquired from The Cancer Genome Atlas database. A prognostic model was constructed using consensus clustering, univariate Cox regression, and LASSO regression. ROC curves, Kaplan-Meier plots, and calibration curves were employed to assess the predictive capacity of the model, while ssGSEA, TIDE, and IPS were used to evaluate the response of high-and low-risk groups to immunotherapy. Drug sensitivity was assessed with the "oncoPredict" R package. Given that we identified a strong association between PLAAT1 and CD8+ T-cell infiltration, this gene was selected for loss-of-function assays in UCEC cells, including the evaluation of their proliferative, invasive, and migratory potential. Results: An eight-gene (LAMP3, RNF183, EEF1A2, PLAAT1, ELAPOR1, B4GALT1, ATP10B, and PLA2G10) risk signature based on lipid metabolism and lysosomal function was constructed to distinguish high-risk and low-risk UCEC patients. Subsequent analyses showed that patients classified as high risk had higher TIDE scores, whereas those categorized as low risk exhibited higher MSI scores and greater levels of CD8+ T-cell infiltration.All evidence suggested that patients in the low-risk group displayed greater immunogenicity and sensitivity to both immunotherapy and chemotherapy. Analysis using the TIMER database indicated that among the eight risk genes, PLAAT1 showed the strongest association with CD8+ T-cell immune infiltration in UCEC. Cytological experiments confirmed that the knockdown of PLAAT1 effectively suppressed the proliferation and motility of endometrial cancer cells. Conclusions: We constructed a 2 risk prognostic model for UCEC based on a combination of lysosomal-and lipid metabolism-related genes. Our findings highlight the oncogenic potential of PLAAT1 in endometrial cancer and provide novel insights into the diagnosis and therapy of this cancer type.
Keywords: Lipid Metabolism, Lysosome, Prognostic signature, Immunotherapy, Uterine corpus endometrial carcinoma
Received: 16 Mar 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Zhu, Yang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shu Zhang, Department of Gynecology & Obstetrics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200000, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.